Corporate Presentation January 2019 Transforming Molecularinformation into action
Disclaimer The presentation and the information it contains do not constitute an offer to sell or subscribe for on the solicitation of an offer to buy or subscribe for securities in any country. This presentation should not be used as a basis for the purchase of shares in IntegraGen (the “Company”) . The distribution of this presentation may be against the law in some countries. The securities described in this presentation have not been and will not be registered under the U.S. Securities act of 1933 as amended (the “US Securities Act”) and therefore cannot be offered or sold in the U.S. unless exempted from the registration requirements of the U.S. Securities Act. Any public securities offer in the U.S. will be carried out through a prospectus available from the Company containing detailed information about the Company, its management Team, and its financial statements. The Company does not intend to register any, or all of this securities offered in the U.S. or to make a public securities offer in the U.S. The Company shall not be held liable for any losses or damages resulting from the use of this document or the information it contains. The Company does not make any express or implied guarantee that the information contained in this document is free from errors or omissions. None of the information contained in this document should be considered as a commitment or a guarantee provided by the Company. This documents contents forward-looking statements and comments about the Company’s strategy and objectives. The Company may not be able to reach these objectives and the Company is under no obligation to update the forward-looking statements. Actual results may differ materially from those expressed or implied in the forward-looking statements. The forward looking statements involve inherent uncertainties and are subject to numerous risk factors such as those described in the Company’s registration document. Past performance is not an indication of future performance and persons in need of advice should contact an independent financial advisor Transforming Molecularinformation into action 2
150 years of genetics at a glance 1953 1961 1866 1900 1934 1980 2000 2008 Watson Jacob- Mendel Devries Mohr Sanger HGP Solexa & Crick Monod Human genome Massively project: 1 st Inheritance parralel Rediscovery First atlas Double helix Genes & Gene human of patterns sequencing of Mendel "Genetics & structure & gene sequencing genome – plant technology, work Diseases" genetic code expression technology entirely hybridation "1000$ sequenced genome" (3years, $5bn) Transforming Molecularinformation into action IntegraGen |Confidential 3
IntegraGen at a Glance 2000 2006 2009 2014 2015 2016 2017 2018 Genomic IPO on on st cl Lau Launch of of Launch of Lau of SI SIRIU RIUS & Res esearch 1 st Ins nstitut Pas asteur First onc Fir oncology clinical Company fou ounded services ser s Eur Euronext xt miR iRpredX MER ERCURY Agreement Agr seq sequencing bio biomarker seq sequencing in in Evry, Fr France platform pla Growth with ith APH APHP pla platform in in EU EU platform pla CE E mar arking patent pa Seq SeqOIA con ontract launched lau (ALINT) (ALI Description Executive Management ▪ Public offering on Euronext Bernard Courtieu, DVM, MDA Emmanuel Martin, R.Ph. CEO Growth in 2014 VP, IntegraGen Genomics ▪ 2017 Revenues: € 6,4m ▪ HQ in Evry’s Genopole, offices Laurence Riot-Lamotte Catherine David in Paris & Cambridge (Mass, US) CFO Quality director ▪ 40 employees Bérengère Genin Larry Yost, RPh Head of Bio-IT GM, IntegraGen Inc.
IntegraGen: What we do Genomics Diagnostics Large scale sequencing services • DNA & RNA • Biomarker sequencing Researchers identification • Transcriptomics • Advanced bio- Nucleic • Epigenomics acid statistics • SNP genotypng • Companion Dx in • Adanced Bio- Bio-Informatics CRC & lung informatics cancer consulting IVD diagnostic kits miR-31-3p Clinicians Transforming Molecularinformation into action 5
IntegraGen, key figures & potential markets IntegraGen Revenues – H1 2016 – H1 2018 in million Employees 44 4,000 0,040 3,500 Rev 2017 / H1 18 6,3 m€ / 3,7 m€ 0,906 Diagnostic 0,111 3,000 Cash burn 2017 / Clinical Research 2,1 m€ / 0,8 m€ 2,500 0,807 H1 18 1,097 Genomics R&D Genomics 2,000 Cash Dec 31 st 2017 4,1 m€ 2,678 2,078 1,500 1,880 NGS Market 2020 1,000 $20B T.A.M. Diag (31-3p H1 2016 H1 2017 H1 2018 NGS Market 2020 120 m€ mCRC) $20B CAGR : 20.7% $ T.A.M. Genomics 20 bn $ $ NGS Data Analysis Market 2020 NGS Data Analysis Market 2020 T.A.M. Software 1,15 bn $ $1.15B $1.15B Sources: Grand View Research Inc, Global Market Research Inc, Ilumina CEO statement
Business switch has shown recovery since 2015 Genomics Revenues in million € In K euros 2018 2017 2016 7 Genotyping 248 337 421 6 1,8 0,4 Sequencing 4 334 3 523 3 651 2,2 1,8 5 1,4 Geco 210 220 169 Software 261 Clinical Genomics 4 R&D Sub-total R&D 5 044 4 080 4 241 5,6 5,4 5,1 3 GR 1 002 1 367 1 137 4,7 - 4,6 4,2 4,2 4,1 Pasteur 816 671 645 3,2 2 2,8 2,3 Sub-total Clinical 1 817 2 038 1 782 1 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 Dx 90 140 Total 6 940 6 118 6 023 Transforming Molecularinformation into action IntegraGen Confidential 7
Genomics Transforming Molecularinformation into action
We provide three levels of Genomic Services Primary data filtering/analysis Sequencing with raw data Detailed data analysis with expert (including bioinformatic tools to output provided to customers biostatical support support direct analysis by customers) Transforming Molecularinformation into action 9
IntegraGen operates a cancer dedicated, industrial platform that provides integrated sequencing + support to interpretation 2. Nucleic acids reception 3. Librairies preparation 1. Sample prep 4. NGS 7. Variants validation & report editing SaaS based, cloud enabled proprietary interpretation software tool Tumor Board 6. Variants selection 5. Bio-informatic analysis IntegraGen Transforming Molecularinformation into action 10
MERCURY: from sequencer to clinical research report Transforming Molecularinformation into action 11
Prioritization of genes and variants with access to numerous databases Transforming Molecularinformation into action 12
MERCURY Databases: Optimized automated bioinformatics pipeline MERCURY incorporates the following genomic databases for fusions : ▪ Cosmic ▪ SIFT ▪ ChimerDB 2.0 database ▪ ClinVar ▪ GENCODE ▪ Cancer Genome Project (CGP) database ▪ TCGA ▪ HGMD-PUBLIC ▪ The Cancer Genome Atlas ▪ Fusion genes found in the The Cancer Genome Atlas consortium RNA-seq ▪ OMIM ▪ ESP, NHLBI Exome dataset Sequencing Project ▪ PUBMED ▪ Fusion genes found in a RNA-seq dataset of 272 glioblastomas from the ▪ DGIDB following publication: https://genome.cshlp.org/content/24/11/1765 ▪ GnomAD ▪ Fusion genes found in a oesophageal tumors from TCGA samples from the ▪ Uniprot ▪ Polyphen following publication: https://www.nature.com/articles/nature20805 ▪ DGV ▪ Oncogenes - when one or both genes are a known oncogene according to ONGENE database: http://ongene.bioinfo-minzhao.org/index.html MERCURY also has direct links to the following datasets/ ▪ When one or both genes are associated with cancer according to Cancer Gene database which provide identity cards and annotations for database: http://www.bushmanlab.org/links/genelists genes of interest: ▪ When one or both genes are proto-oncogene or tumor suppressor genes ▪ Genecards according to the UniProt database: http://www.uniprot.org/ ▪ Tumor Portal ▪ Known fusion genes found in pancreatic tumors based on the following ▪ Cosmic publication: http://dx.doi.org/110.1038/nature16965 ▪ NCBI/PUBMED ▪ Known fusion genes found in 150 prostate tumors RNAs from the following ▪ Ace View publication: http://dx.doi.org/10.1016/j.cell.2015.05.001) ▪ Gene Ontology Transforming Molecularinformation into action 13
IntegraGen and SeqOIA, key contributors of the "France Medecine Génomique 2025" plan June 2016 July 2017 Aug 2018 670 m€ SeqOIA (Paris The SeqOIA April – July financing over 5 Region) & GCS selects 2018 years for the AuraGen (Lyon Dec 2016 – July IntegraGen to 2015-2016 implementation Region) are 2017 be the RFP issued to of 12 genomic selected to be operator of the Establishment select the platforms, a the 2 pilot RFP issued to SeqOIA of the FMG industrial data center & a platforms select the first 2 sequencing 2025 plan operator of Génomic Center pilot platforms platform, to the SeqOIA of Excellence produce Platform, "Bringing France into the sequencing era of genomic medicine" data 17 to 25m€ services over 5 years Transforming Molecularinformation into action IntegraGen |Confidential 14
Recommend
More recommend
